Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Merrouche

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Oncoimmunology|July 29, 2016
Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytesA De Masson, J Giustiniani, A Marie-Cardine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimenT André, M A Bensmaine, C Louvet, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2002
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancerM Ychou, J L Raoul, F Desseigne, et al.
British Journal of Cancer|September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?C Massard, J-J Voigt, A Laplanche, et al.
British Journal of Cancer|August 14, 2003
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)R Bugat, A Bataillard, T Lesimple, et al.
The Journal of Urology|August 21, 2002
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier, J P Droz, F Rolland, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 25, 2004
[Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach--radiotherapy]M Ychou, G Gory-Delabaere, P Blanc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapyP Rougier, R Bugat, J Y Douillard, et al.
Bulletin Du Cancer|October 2, 2001
[Standards, options and recommendations: practice guidelines for difficult diagnosis in surgical pathology or cytopathology in cancer patients]J M Coindre, M P Blanc-Vincent, F Collin, et al.
ESMO Open|May 13, 2021
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in FranceJ Y Blay, S Boucher, B Le Vu, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Oncoimmunology|July 29, 2016
Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytesA De Masson, J Giustiniani, A Marie-Cardine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimenT André, M A Bensmaine, C Louvet, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2002
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancerM Ychou, J L Raoul, F Desseigne, et al.
British Journal of Cancer|September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?C Massard, J-J Voigt, A Laplanche, et al.
British Journal of Cancer|August 14, 2003
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)R Bugat, A Bataillard, T Lesimple, et al.
The Journal of Urology|August 21, 2002
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier, J P Droz, F Rolland, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 25, 2004
[Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach--radiotherapy]M Ychou, G Gory-Delabaere, P Blanc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapyP Rougier, R Bugat, J Y Douillard, et al.
Bulletin Du Cancer|October 2, 2001
[Standards, options and recommendations: practice guidelines for difficult diagnosis in surgical pathology or cytopathology in cancer patients]J M Coindre, M P Blanc-Vincent, F Collin, et al.
ESMO Open|May 13, 2021
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in FranceJ Y Blay, S Boucher, B Le Vu, et al.
Pageof 6